Imiquimod-induced regression of actinic keratosis is associated with infiltration by T lymphocytes and dendritic cells: A randomized controlled trial

British Journal of Dermatology

Volumn 154, Issue 1, 2006, Pages 72-78

  Ooi, T ^a   Barnetson, R Stc ^a   Zhuang, L ^a   McKane, S ^b   Lee, J H ^b   Slade, H B ^b   Halliday, G M ^a  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^b 3M COMPANY   (United States)

Author keywords

Actinic keratosis; Cell mediated immune response; Imiquimod; Randomized controlled trial

Indexed keywords

IMIQUIMOD;

ACTINIC KERATOSIS; ADULT; AGED; APPLICATION SITE REACTION; ARTICLE; CELL INFILTRATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG MECHANISM; ERYTHEMA; FEMALE; FLU LIKE SYNDROME; HEADACHE; HUMAN; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS;

AGED; AMINOQUINOLINES; BIOLOGICAL MARKERS; CELL MOVEMENT; DENDRITIC CELLS; DOUBLE-BLIND METHOD; DRUG ERUPTIONS; ERYTHEMA; FEMALE; HUMANS; IMMUNOPHENOTYPING; INTERFERON INDUCERS; KERATOSIS; MALE; MIDDLE AGED; PHOTOSENSITIVITY DISORDERS; SKIN; T-LYMPHOCYTE SUBSETS; TREATMENT OUTCOME;

EID: 33644927271     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2005.06932.x     Document Type: Article

References (35)

1. Stingl G Gazze-Stingl L Aberer W Wolff K Antigen presentation by murine epidermal Langerhans cells and its alteration by ultraviolet B light J Immunol 1981 127 1707 13
2. Moodycliffe AM Nghiem D Clydesdale G Ullrich SE Immune suppression and skin cancer development: regulation of NKT cells Nat Immunol 2000 1 521 5
3. Cockerell C Histopathology of incipient intraepidermal squamous cell carcinoma ('actinic keratosis') J Am Acad Dermatol 2000 42 Suppl. S11 17
4. Marks R Rennie G Selwood TS Malignant transformation of solar keratoses to squamous cell carcinoma Lancet 1988 i 795 7
5. Marks R Foley P Goodman G et al. Spontaneous remission of solar keratoses: the case for conservative management Br J Dermatol 1986 115 649 55
6. Callen JP Bickers DR Moy RL Actinic keratoses J Am Acad Dermatol 1997 36 650 3
7. Pfister H Fuchs PG Majewski S et al. High prevalence of epidermodysplasia verruciformis-associated human papillomavirus DNA in actinic keratoses of the immunocompetent population Arch Dermatol Res 2003 295 273 9
8. Meyer T Arndt R Christophers E et al. Importance of human papillomaviruses for the development of skin cancer Cancer Detect Prev 2001 25 533 47
9. Frost CA Green AC Epidemiology of solar keratoses Br J Dermatol 1994 131 455 64
10. Green A Whiteman D Frost C Battistutta D Sun exposure, skin cancers and related skin conditions J Epidemiol 1999 9 S7 13
11. Moy RL Clinical presentation of actinic keratoses and squamous cell carcinoma J Am Acad Dermatol 2000 42 S8 10
12. Marks R The epidemiology of non-melanoma skin cancer: who, why and what can we do about it J Dermatol 1995 22 853 7
13. Tucci M Offidani A Lucarini G et al. Advances in the understanding of malignant transformation of keratinocytes: an immunohistochemical study J Eur Acad Dermatol Venereol 1998 10 118 24
14. Einspahr J Alberts DS Aickin M et al. Expression of p53 protein in actinic keratosis, adjacent, normal-appearing, and non-sun-exposed human skin Cancer Epidemiol Biomarkers Prev 1997 6 583 7
15. Schwarz T Photoimmunosuppression Photodermatol Photoimmunol Photomed 2002 18 141 5
16. Lebwohl M Dinehart S Whiting D et al. Imiquimod 5% cream for the treatment of actinic keratosis: results from two phase III, randomized, double-blind, parallel group, vehicle-controlled trials J Am Acad Dermatol 2004 50 714 21
17. Gibson S Lindh J Riter T et al. Plasmacytoid dendritic cells produce cytokines and mature in response to the TLR7 agonists, imiquimod and resiquimod Cell Immunol 2002 218 74 86
18. Salasche S Levine N Morrison L Cycle therapy of actinic keratoses of the face and scalp with 5% topical imiquimod cream: an open-label trial J Am Acad Dermatol 2002 47 571 7
19. Stockfleth E Meyer T Benninghoff B et al. A randomized, double-blind, vehicle-controlled study to assess 5% imiquimod cream for the treatment of multiple actinic keratoses Arch Dermatol 2002 138 1498 502
20. Sziemies RM Gerritsen MP Gupta G et al. Imiquimod 5% cream for the treatment of actinic keratosis: results from a phase III, randomized, double-blind, vehicle-controlled, clinical trial with histology J Am Acad Dermatol 2004 51 547 55
21. Suzuki H Wang BH Shivji GM et al. Imiquimod, a topical immune response modifier, induces migration of Langerhans cells J Invest Dermatol 2000 114 135 41
22. Hemmi H Kaisho T Takeuchi O et al. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway Nat Immunol 2002 3 196 200
23. Sauder DN Imiquimod: modes of action Br J Dermatol 2003 149 Suppl. 66 5 8
24. Schwarz A Grabbe S Aragane Y et al. Interleukin-12 prevents ultraviolet B-induced local immunosuppression and overcomes UVB-induced tolerance J Invest Dermatol 1996 106 1187 91
25. Tefany F Barnetson RStC Halliday GM et al. Immunocytochemical analysis of the cellular infiltrate in primary regressing and non-regressing malignant melanoma J Invest Dermatol 1991 97 197 202
26. Testerman TL Gerster JF Imbertson LM et al. Cytokine induction by the immunomodulators imiquimod and S-27609 J Leukoc Biol 1995 58 365 72
27. Ito T Amakawa R Kaisho T et al. Interferon and interleukin-12 are induced differentially by toll-like receptor 7 ligands in human blood dendritic cell subsets J Exp Med 2002 195 1507 12
28. Tomai MA Ahonen CL Couture AM et al. Effects of the imidazoquinolines, imiquimod and S-28463, on Th1 and Th2 cytokine responses in vitro J Dermatol Sci 1998 16 S180
29. Barnetson RStC Satchell A Zhuang L et al. Imiquimod-induced regression of clinically diagnosed superficial basal cell carcinoma is associated with early infiltration by CD4 T cells and dendritic cells Clin Exp Dermatol 2004 29 639 43
30. Smith K Hamza S Skelton H Topical imidazoquinoline therapy of cutaneous squamous cell carcinoma polarized lymphoid and monocyte/macrophage populations to a Th1 and M1 cytokine pattern Clin Exp Dermatol 2004 29 1 8
31. Mackenzie-Wood A Kossard S de Launey J et al. Imiquimod 5% cream in the treatment of Bowen's disease J Am Acad Dermatol 2001 44 462 70
32. Schon M Bong AB Drewniok C et al. Tumor-selective induction of apoptosis and the small-molecule immune response modifier imiquimod J Natl Cancer Inst 2003 95 1138 49
33. Meyer T Nindl I Schmook T et al. Induction of apoptosis by Toll-like receptor-7 agonist in tissue cultures Br J Dermatol 2003 149 Suppl. 66 9 13
34. Vidal D Matias-Guiu X Alomar A Efficacy of imiquimod for the expression of Bcl-2, Ki67, p53 and basal cell carcinoma apoptosis Br J Dermatol 2004 151 656 62
35. Berman B Sullivan T De Araujo T Nadji M Expression of Fas-receptor on basal cell carcinomas after treatment with imiquimod 5% cream or vehicle Br J Dermatol 2003 149 Suppl. 66 59 61